Nektar Therapeutics Reports Positive Clinical Trial Results for Hair-Loss Drug
Nektar Therapeutics (NASDAQ: NKTR) saw its stock rise over 18% after reporting positive phase 2b trial results for its drug rezpegaldesleukin, which showed improved hair growth in patients with alopecia areata. The trial excluded ineligible patients from a previous study, leading to more promising outcomes. The company plans to advance the drug to later-stage trials.
Topics: biotech clinical trial results hair-loss treatment Nektar Therapeutics stock price movement